



## ASX ANNOUNCEMENT

8 January 2024

### Appointment of Chief Financial Officer/ Company Secretary

---

**8 January 2024** – Cann Group Limited (ASX: CAN) (Cann or the Company) announced today that Tony Di Pietro has been appointed to the role of Chief Financial Officer (CFO), commencing on 8 April 2024. Mr Di Pietro will replace Deborah Ambrosini, who left Cann Group on 22 December 2023.

In addition to the CFO role, Mr Di Pietro will act as joint Company Secretary with Steven Notaro, Head of Legal and Regulatory Affairs at Cann Group.

Having spent the past two decades at ASX-listed companies, Mr Di Pietro boasts extensive experience as CFO/Company Secretary in the med-tech industry, with his last three roles at Sienna Cancer Diagnostics Limited (November 2014 – July 2020), INOVIQ Limited (July 2020 – November 2022) and Genetic Technologies Limited (November 2022 – present).

In his most recent role at Genetic Technologies, Mr Di Pietro managed a capital raising of US \$5 million from US-based investors and was responsible for both US and Australian due diligence activities and compliance with both ASX/Corporations Act & NASDAQ/SEC regulations.

Mr Di Pietro's qualifications include:

- A Bachelor of Commerce (BCom), Accounting and Finance, from Swinburne University of Technology;
- Chartered Accountants (CA) accreditation (1989-2000);
- Graduate Diploma of Applied Corporate Governance from the Governance Institute of Australia (2012 - 2014); and
- Completed the Company Directors Course at the Australian Institute of Company Directors in 2018.

Chief Executive Officer, Peter Koetsier, said Cann is extremely pleased to welcome someone of Mr Di Pietro's calibre and experience to the Company.

*"We are very excited to announce Tony's appointment to the role of CFO and joint Company Secretary. He has a brilliant track record of helping to oversee the successful evolution of smaller companies into established successful operations that generate outstanding profits. With the Mildura facility now at maximum capacity, the next stage of Cann Group's evolution is to become a strong commercial success and move to being EBITDA positive as soon as possible. We are looking forward to Tony's expertise helping to facilitate this growth phase for Cann Group."*

**Authorised for release by the Board of Directors, Cann Group Limited.**

**For all media enquiries please contact:**

Jackson Paine  
Corporate Communications Manager  
+61 439 492 955  
[jackson.paine@canngrouplimited.com](mailto:jackson.paine@canngrouplimited.com)

**For all other information please contact:**

Peter Koetsier  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[peter.koetsier@canngrouplimited.com](mailto:peter.koetsier@canngrouplimited.com)

Steven Notaro  
Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[steven.notaro@canngrouplimited.com](mailto:steven.notaro@canngrouplimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

**Learn more at:** [www.canngrouplimited.com](http://www.canngrouplimited.com) | [www.satipharm.com](http://www.satipharm.com)